Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma

Administering chemotherapy until progression to metastatic pancreatic ductal adenocarcinoma (PDAC) patients lacks of supporting evidence and causes cumulative toxicity. We explored the role of cyclophosphamide as maintenance therapy.

Source: Digestive and Liver Disease - August 14, 2023 Category: Gastroenterology Authors: Michele Reni, Umberto Peretti, Marina Macchini, Giulia Orsi, Annamaria Militello, Assunta Briccolani, Massimo Falconi, Stefano Cascinu Tags: Oncology Source Type: research